INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a CD5 + B-cell malignancy that is still considered incurable, although novel treatment combinations of monoclonal antibodies and chemotherapy 1 seem promising. Many patients eventually develop drug resistance through several pathways including mutation of the p53 tumor suppressor gene, or involving the gene encoding the ataxia telangectasia mutated (ATM), which is a kinase required for p53 function. Such genetic lesions are uncommon in CLL at diagnosis, but increase in frequency as the disease progresses 2 . Since the cytoreductive activity of most current chemotherapeutic agents requires functional p53, loss of p53 is associated with drug resistance and poor prognosis 3 . Because of these aspects, different agents with p53-independent modes of action are clearly needed.
CLL has been considered a smoldering disease characterized by long-lived tumor cells arrested in the G 0 /G 1 -phase of the cell cycle and possessing intrinsic apoptosis defects 4 . This concept was largely based on analyses of peripheral blood derived CLL cells. A study of in vivo cellular kinetics however suggested that CLL is a dynamic disease with substantial proliferation rates as well as increased death rates compared to normal B-cells 5 . Prior to this, it was already known that proliferation and especially increased survival of the malignant B-cells may not result primarily from intrinsic defects, but appear to depend largely on interactions with microenvironmental bystander cells. Interactions between CLL cells and follicular dendritic cells, bone marrow stromal cells, IL-6-producing endothelial cells, SDF-producing nurselike cells, or CD40L expressing CD4 + T cells cells [6] [7] [8] [9] have been shown to increase the apoptotic threshold in vitro. In a recent comparative survey of apoptosis regulatory genes and proteins in neoplastic B-cells derived from CLL lymph node (LN) proliferation centers and from peripheral blood 10 , we observed specifi c changes including increased expression of anti-apoptotic proteins such as Mcl-1, Bcl-xL and A1/Bfl -1 in LN cells.
Extended cell survival of tumor cells within the LN microenvironment may create an intracellular milieu permissive for genetic instability and for the accumulation of gene mutations that favors disease progression. Furthermore, these microenvironmental interactions may provide a safe haven from cytotoxic anticancer drugs, thus serving as a tumor reservoir from which relapse occurs (reviewed by Pedersen and Reed 11 ). This concept is supported by the observation that prolonged CD40 activation, which to a large extent recapitulates the anti-apoptotic expression profi le of LN derived CLL cells, renders CLL cells resistant to current chemotherapeutics 12;13 . The currently widely applied drug fl udarabine relies on an intact p53 response which induces expression of the Bcl-2 member Puma, thereby triggering apoptosis [14] [15] [16] . Alternative, p53-independent drugs such as the proteasome inhibitor bortezomib or the cyclin Chapter 6 ▪ c-Abl inhibitors prevent drugresistance in CLL 119 dependent kinase inhibitor roscovitine engage other pro-apoptotic Bcl-2 members such as Noxa and Bim. Especially Bim is a potent pro-apoptosis member of the BH3only subgroup of the Bcl-2 family, engaged by a variety of apoptotic triggers [17] [18] [19] [20] . A potential means of suppressing the lethal capacity of Bim involves the pro-survival kinase ERK. In model systems activation of ERK leads to phosphorylation and subsequent proteasomal degradation of the Bim EL splice variant 21;22 .
In the present study we used in vitro CD40 stimulation as a model for chemoresistant LN CLL, and searched for means to circumvent it. CD40 stimulation of CLL cells strongly induced Bcl-xL, Mcl-1 and A1/Bfl -1 proteins, resulting in a broad drug resistance. Various aspects of this anti-apoptotic program also occur in chronic myeloid leukemia (CML), a disease for which current treatment includes kinase inhibitors that were developed to target BCR-Abl signaling 23 . Therefore, we next applied the c-Abl inhibitors imatinib (Gleevec, STI-571) or dasatinib (Sprycel, BMS-354825) in conjunction with CD40. Both drugs caused a profound reversal of the protective CD40 effects, and restored drug sensitivity. Probing of LN CLL samples demonstrated that in these protective niches similar pro-survival signaling pathways are active as upon CD40 triggering in vitro. Collectively, these data suggest that CLL cells residing in LN might be therapeutically targeted by drug combinations that include c-Abl inhibitors.
MATERIALS AND METHODS

Patient material
Patient material was obtained after routine diagnostic or follow-up procedures at the departments of Hematology and Pathology of the Academic Medical Center Amsterdam. This study was conducted after informed consent and approved by the AMC medical committee on human experimentation, in agreement with the Helsinki Declaration of 1975, revised in 1983. Lymph node (LN) material, diffusely infi ltrated by CLL cells, was freshly frozen in liquid nitrogen directly after surgical removal.
Immunohistochemical analysis of these lymph nodes revealed that greater than 90% of the tissue consisted of tumor cells 10 . Peripheral blood (PB) mononuclear cells 
RNA isolation and RT-MLPA
Total RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit (Sigma Aldrich). Reverse transcription-multiplex ligation-dependent probe amplifi cation assay (RT-MLPA) procedure was performed as described previously 16;24 .
Reagents
The proteasome inhibitor bortezomib was obtained from Janssen-Cilag (Tilburg 
Analysis of apoptosis, Western Blot and antibodies
For apoptosis induction, cells at a density of 1.5.10 6 /ml in culture medium were treated with 100μM fl udarabine (48 hrs), 30nM bortezomib, 25 μM roscovitine or 5 μM GSI1 (24 hrs), and stained with 200 nM MitoTracker Orange (Molecular Probes, Leiden, The Netherlands) for 30 minutes at 37°C and analysed by FACS. Western blotting was performed as described previously 16 . Cells were lysed in Laemmli Sample Buffer, and samples (10-30 μg protein) were separated by 13% sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% gels for ERK). To screen for p53 functionality, cells were irradiated (5Gy) and after O/N incubation tested for the expression of p53 and p21 by western blot analysis as described before 25 
In vitro CD40 stimulation and cell lines
BCR-Abl positive K562 cells and NIH3T3 fi broblasts were cultured in IMDM as described above for CLL cells. CD40-ligand (CD40L, CD154) was expressed on NIH3T3 fi broblasts, stably transfected with a plasmid encoding human CD40L.
Fibroblasts were irradiated (30Gy) and plated in culture-treated 6-wells plates (6x 10 5 cells/well). CLL cells were thawed and 5 x 10 6 cells per well were added to the adhered fi broblasts in 3 ml IMDM containing 10% FCS and incubated for 48 hrs at 37 o C. To test the effect of c-Abl kinase inhibitors, imatinib and dasatinib, and the effect of Erkinhibitor PD-58059, CLL cells were pre-treated with 80 μM imatinib or dasatinib, or 50 μM PD-58059 for 30 minutes. After pre-incubation CLL cells were stimulated for 48 hrs at 37 o C with CD40L with or without 30 μM imatinib or dasatinib or 50 μM PD-58059. In the case of dasatinib, also other regimens and concentrations were used, where CLL cells were fi rst co-cultured for 48 hrs with CD40L-expressing or control 3T3 fi broblasts, detached and washed and subsequently incubated in medium for an additional 48 hrs in the presence of varying dasatinib concentrations (30nM-30μM), followed by testing sensitivity to cytotoxic drugs, as described above.
RESULTS
Prolonged CD40 stimulation of CLL cells results in broad drug resistance, which is independent of ERK-mediated decrease in
BimEL levels
In vitro stimulation via CD40 renders CLL cells resistant to fl udarabine and induces expression of various anti-apoptotic proteins such as Bcl-xL and A1/Bfl -1 via de novo transcription 12;13;26 . In addition to previously described transcriptional effects of prolonged CD40 triggering, several novel effects on protein levels of various apoptosis regulators were observed. In particular, the Bim EL splice variant decreased while Mcl-1 levels increased (see Fig. 1A ).
Since it is known that ERK signaling can affect Bim EL protein levels in model systems 21;27 this aspect was investigated further. Over the course of several days of CD40 stimulation, a signifi cant reduction in Bim EL protein levels occurred, although Bim mRNA levels remained constant 10 (see also Fig. 4 below) . In Figure 1B , the larger two Bim species represent Bim EL and most presumably a splice variant Bimα1 28 , which became visible in certain samples upon prolonged migration in SDS-PAGE.
Under the experimental conditions applied a short-lived phosphorylated form of Bim (p-Bim) is probably also present 21 , but in our hands this form of Bim could not be observed in primary samples either with the antibody used here, nor with commercial antibodies specifi cally generated against p-Bim. The activation status of ERK upon CD40 triggering was increased, and addition of the specifi c ERK inhibitor PD-98059 during CD40 stimulation prevented the reduction of Bim EL (Fig. 1C ). Addition of the proteaseome inhibitor MG132 after CD40 stimulation demonstrated that Bim EL levels
Figure 1. Anti-apoptotic changes in CLL cells upon CD40 stimulation include ERK-mediated decrease in Bim EL levels. (A)
Changes in expression of apoptosis regulators upon 48 hrs CD40 triggering were monitored by Western blot for the indicated proteins. Results are from a representative CLL sample from >10 patients studied. Equal protein loading was confi rmed by staining for actin as loading control. (B) Time course of Bim EL decrease monitored in 2 CLL samples. Shown are samples taken on consecutive days of co-culture in absence or presence of CD40 stimulation. In sample 11-166 a decrease in Bim EL can be observed on day 2, and in sample 12 on day 1. Position of Bim EL is indicated by a triangle, the faster migrating species is probably the Bimα1 splice variant. (C) Effects of ERK inhibition on Bim EL levels and phosphorylated ERK. CLL cells were stimulated with CD40 in the presence of ERK inhibitor as indicated, and lysates were probed for Bim protein, phosphorylated and total ERK levels.
were controlled via increased protein turnover, confi rming previous reports 21;22;29 (data not shown).
Next, CLL cells triggered via CD40 in the absence or presence of ERK inhibition were
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investigated for sensitivity to drugs that are in current clinical use or in preclinical development. As can be seen in fi gure 2. prolonged CD40 stimulation rendered the cells resistant to fl udarabine, as observed before 12;13 ,the proteasome inhibitor bortezomib and the cyclin-dependent kinase inhibitor roscovitine. In addition, the γ-secretase inhibitor GSI-1 was included, which is considered to be an inhibitor of Notch signaling 30 . We have recently observed that GSI-1 is in fact an inhibitor of the proteasome and a potent inducer of apoptosis in CLL (Hallaert et al., submitted) .
CD40 triggering also rendered CLL cells resistant to GSI-1. For multiple CLL isolates tested, addition of ERK inhibitors did not alleviate the broad drug resistance afforded
Figure 2. Broad drug resistance of CLL cells upon CD40 stimulation is not prevented by ERK inhibition.
CLL cells were co-cultured with control 3T3 (control) or CD40L-expressing cells for 48 hrs, in the presence of ERK inhibitor PD-98059 as indicated. After detachment and washing, cells were incubated with the indicated drugs as described in detail in Methods, and analyzed for apoptosis by MitoTracker staining after 24 hrs (roscovitine, bortezomib and GSI-1) or 48 hrs (fl udarabine). Cells cultured on 3T3 cells (black bars) are sensitive to all drugs, but CD40 stimulation (white bars) confers broad drug resistance and this is maintained when ERK is inhibited (grey bars). The data shown for untreated samples (medium) were measured at 24hr. Apoptosis levels of medium samples at 48hrs were comparable. via prolonged CD40 stimulation ( Fig. 2 ). Together these data indicate that although CD40 signaling activates ERK and thereby causes a decline in Bim EL levels, this is not the cause for the observed broad drug resistance.
c-Abl inhibors prevent the anti-apoptotic protein profi le of CD40treated CLL cells
Another aspect of prolonged CD40 triggering of CLL cells was an increase in Mcl-1 protein (see Fig. 1A ) which was, similar to the changes in Bim, independent from increased transcription (see also below). Mcl-1 has recently been recognized as promising target for drugs 31 , and has been implicated in anti-apoptotic signaling via BCR-Abl in chronic myeloid leukemia [32] [33] [34] . Furthermore, other anti-apoptotic changes in our in vitro CD40-CLL system, such as increased Bcl-xL and decreased Bim, have also been implicated in BCR-Abl signaling 32;35-37 . Lastly, it was recently reported that c-Abl protein expression correlates positively with tumor burden and disease stage in CLL 38 . Therefore, we next tested the c-Abl inhibitor STI-571/gleevec/imatinib as a potential suppressor of CD40-mediated pro-survival effects in CLL cells. In 
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Relative expression
This compound has a higher specifi c activity towards c-Abl, but is also less specifi c for Abl kinase and targets other kinases such as Btk, Lyn and Tec 23;39 . The effects of imatinib and dasatinib with respect to reversing the CD40 effects on pro-survival parameters were also observed in CLL cells with a dysfunction in the p53 pathway ( Fig. 3, right panel) .
The various kinase inhibitors were also monitored for their effects on transcription using a multiplex assay able to quantify expression of 34 apoptosis regulatory genes.
As described previously, prolonged in vitro CD40 stimulation of CLL cells induces transcription of Bcl-xL and A1/Bfl -1, as well as a reduction in Noxa 10;13 . For the ERK inhibitor PD-98059 no effects on transcription of these genes were found. In contrast, the c-Abl inhibitors prevented upregulation of Bcl-xL and A1/Bfl -1 transcripts, while for example Mcl-1 and Bim transcripts were hardly affected by these drugs (Fig. 3B black bars), although they did display changes at the protein level (Fig. 3A) . The effects of the Abl kinase inhibitors on Bcl-xL and A1/Bfl -1 were similar to those observed when CLL cells were exposed to NF-κB inhibitor BAY-11-7082 during stimulation via CD40
( Supplementary Fig. 1 ). The inhibitory effects of especially dasatinib on Bcl-xL and A1/Bfl -1 transcription were also detected in cells with a dysfunctional p53 response 
Contribution to drug resistance of pro-survival proteins probed by ABT-737
Anti-apoptotic Bcl-2 family members can be counteracted by BH3 mimetics such as ABT-737, a widely studied compound in preclinical development 40 . ABT-737 is very effective against Bcl-2 and Bcl-xL, but does not bind to Mcl-1 or A1/Bfl -1 31;41 .
As reported before 42 , CLL cells are quite sensitive to ABT-737, but upon stimulation with CD40 this is reduced approximately 100-fold ( Fig.4 A&B) . We tested whether 
c-Abl kinase inhibitors prevent drug resistance of CD40-treated CLL cells
In a similar fasion as above for ABT-737, the effect of c-Abl kinase inhibitors on the drug resistance afforded by CD40 triggering was measured. The apoptosis-inducing effects of the Abl inhibitors themselves on control samples co-cultured with 3T3 cells and CD40L-expressing cells were minimal (Fig. 5A, medium samples) . Only at high Fig. 4 ).
Remarkably however, imatinib and especially dasatinib prevented the resistance towards various drugs normally observed upon CD40 treatment of CLL cells. This appeared true for CLL samples with mutated as well as unmutated IgV H gene sequences (both n=2). The sensitising effect of these inhibitors was also seen in CLL cells with a dysfunctional p53 pathway (Fig. 5B ). Especially the cytotoxic effect of proteasome inhibitors (bortezomib and GSI-1) was potentiated by treatment of CLL cells with c-Abl inhibitors during CD40 exposure. In general, the effects of dasatinib were stronger than those of imatinib at the concentrations used (30 μM), as was also observed for the effects on protein levels (see Fig. 3 ). Since dasatinib has a higher specifi c activity towards its target kinases than imatinib 23;43 we also tested its effects over a lower range of concentrations. The capacity of dasatinib to modulate the drug sensitivity of CD40-treated CLL cells could also be observed at substantially lower concentrations (30nM-3μM). This is demonstrated in fi gure 5C for the results obtained with GSI-1, which was in general the strongest inducer of apoptosis in CLL cells among the drugs tested.
The results thusfar were obtained with simultaneous administration of CD40 signals and kinase inhibitors. To better refl ect the actual situation of LN CLL cells already exposed to a protective environment, isolated PB CLL cells were fi rst stimulated via CD40 for 48 hrs, followed by separate addition of dasatinib (0.3μM) and drugsensitivity tests. Also in this set-up, a reversal of resistance towards various drugs (fl udarabine, bortezomib, roscovitine) could be observed (Fig. 5D ). Thus, dasatinib has a clear capacity to interfere with the protective effects afforded by prolonged CD40 stimulation.
Similar apoptosis protein signature in ex vivo LN samples as upon in vitro CD40 triggering
To relate the effects of in vitro CD40 stimulation with the in vivo situation, samples from CLL lymph nodes were lysed directly in SDS-containing sample buffer and probed for the presence of proteins involved in apoptosis regulation. As observed before, a clear increase of Bcl-xL protein was present in LN samples compared to peripheral blood (PB) samples 10 . This was also found for Mcl-1 10 and A1/Bfl -1 (data not shown). Regarding the expression levels of other signature proteins involved in CD40-mediated anti-apoptosis pathways, a strong increase in both total and phosphorylated ERK was found, concomitant with decreased levels of Bim EL (Fig. 6 ).
These fi ndings indicate that in CLL lymph nodes similar survival pathways are operational as those that can be induced in peripheral blood CLL cells by prolonged in vitro CD40 stimulation.
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DISCUSSION
Previous reports have described effects of inhibitors of BCR-Abl kinase on single anti-apoptosis proteins (predominantly Mcl-1, Bcl-xL or Bim) in CML or model cell lines [35] [36] [37] . This study provides an overview on the effects of c-Abl inhibitors on all Bcl-2 members in the context of CD40 signaling in CLL cells. The rationale for the present study was two-fold. First, there is the growing concept that CLL is a dynamic disease, with proliferation centers in LN and possibly also BM. These protective niches, where cells are prone to be more drug resistant, are presumably the source of relapsing clones. Second, the potential of novel drugs such as kinase inhibitors, to target prosurvival signaling pathways to which malignant cells have become addicted.
We have observed that our in vitro CLL culture model setting provides strong and probably supra-physiological CD40 signals, with longlasting protective effects which continue after detachment of CLL cells from CD40L cells (data not shown).
Nevertheless, comparison between LN samples and PB CLL cells stimulated in vitro
via CD40 indicated the presence of a comparable pro-survival signature as implied by ERK activation and Bim EL levels. Previously, we have shown that in LN samples also increased levels of Bcl-xL and Mcl-1 are detectable 10 . Together, the available data indicate that the pro-survival signature triggered via CD40 stimulation in vitro is also found in CLL lymph nodes, and imply that our experimental data hold promise for extrapolation towards a therapeutic setting. In our experience, neither imatinib nor dasatinib are effi cient inducers of apoptosis as single agents, in contrast to their effects on K562 cells, which depend for survival on the BCR-Abl fusion oncogene (Supplemental Fig. 3 ). In a recent study, considerable variation in apoptosis susceptibility in untreated and dasatinib-treated peripheral blood samples was found using 5 μM dasatinib, and the response was correlated with IgV H mutation and ZAP70 status 48 . This and other studies performed to date agree that, in CLL cells from peripheral blood, dasatinib has a strong synergistic effect in combination with p53-pathway dependent and -independent agents [48] [49] [50] .
Transcriptional effects of imatinib and dasatinib on Bcl-xL and A1/Bfl -1 were similar to those of inhibitors of NF-κB. We noted that the effects of the c-Abl inhibitors on reversing ERK phosphorylation status, and the corresponding changes in Bim EL levels varied among patients, without apparent correlation with prognostic factors such as mutation or p53 status (data not shown and Fig. 3 ). These signaling pathways are affected/reversed by imatinib and dasatinib although the actual At present, two independent mechanisms are attributed to the development of chemoresistance in CLL. The fi rst is a shift in the balance between pro-and antiapoptotic regulators, and both Mcl-1 55 and Bfl -1/A1 56 have been associated with resistance to chemotherapy. Signifi cantly, these hallmarks are very similar to the CD40-activated CLL phenotype we use as a model. The second mechanism is based on acquired mutations resulting in a dysfunctional p53 response 3 . A recent phase II evaluation of dasatinib as single agent in relapsed and refractory CLL showed limited effects, but in good correlation with our data a reduction of lymph node size was observed in a major fraction of patients 57 . Our data indicate that c-Abl inhibitors, notably dasatinib, overcome the protective profi le within the micro-environment resulting in susceptibility to p53 pathway dependent drugs (fl udarabine) as well as to p53-independent agents (roscovitine, bortezomib, ABT-737). Thus, from a clinical perspective it may be more effective to apply combination strategies of dasatinib 3 Mutated IgV H gene (+) denotes >2% mutations compared to germline sequence. 4 P53 functional status was measured via radiation-induced RNA expression of p53 target genes Puma and Bax, or by p53 and p21 protein upregulation via western blot, as described in refs 16 and 25. Patient 25 had a so-called type A dysfunction. (ND = not determined) 5 As determined by FISH. Probes for 11q22.3 (ATM), 13q14 (D13S319) and 17p13 (TP53) were obtained from Abbott-Vysis. Samples with >10% aberrant signals were considered abnormal. Figure S1 . NF-кB inhibitor BAY-11-7082 blocks CD40-mediated Bcl-xL and Bfl -1 upregulation. CLL cells were stimulated with or without CD40L for 48 hrs in the presence of ERK inhibitor PD-98059 or of BAY-11-7082, an irreversible inhibitor of IκB-α phosphorylation (1 and 5 μM). Cells were lysed in SDScontaining buffer and analyzed by western blot. 
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